Figure 1



Analysis set: PK
Study part: SAD
Day: 1
Mean (+/- SD) Comp. 1 plasma concentration (ng/mL)
2000
1500
1000
500
0
0 2 4 6 8 10 12 24 48 72
Time point (hours)
Treatment
10 mg fasted
30 mg fasted
90 mg fasted
200 mg fasted
90 mg fed
200 mg fed
Linear-Linear scale

Figure 2



Analysis set: PK
Study part: SAD
Day: 1
Mean (+/- SD) Comp. 1 plasma concentration (ng/mL)
10000
1000
100
10
1
0 2 4 6 8 10 12 24 48 72
Time point (hours)
Treatment
10 mg fasted
30 mg fasted
90 mg fasted
200 mg fasted
90 mg fed
200 mg fed
Log-Linear scale

Figure 3



Analysis set: PK
Study part: MAD
Mean (+/- SD) Comp. 1 plasma concentration (ng/mL)
2500
2000
1500
1000
500
0
0 2 4 6 8 10 12 24 48 72
Time point (hours)
Treatment
30 mg qd - Day 1
90 mg qd - Day 1
150 mg qd - Day 1
30 mg qd - Day 10
90 mg qd - Day 10
150 mg qd - Day 10
30 mg qd - Day 13 (+ IFN-alpha challenge on Day 11)
90 mg qd - Day 13 (+ IFN-alpha challenge on Day 11)
150 mg qd - Day 13 (+ IFN-alpha challenge on Day 11)
Lincar-Lincar scalc

Figure 4



Analysis set: PK
Study part: MAD
Mean (+/- SD) Comp. 1 plasma concentration (ng/mL)
10000
1000
100
10
0 2 4 6 8 10 12 24 48 72
Time point (hours)
Treatment
30 mg qd - Day 1
90 mg qd - Day 1
150 mg qd - Day 1
30 mg qd - Day 10
90 mg qd - Day 10
150 mg qd - Day 10
30 mg qd - Day 13 (+ IFN-alpha challenge on Day 11)
90 mg qd - Day 13 (+ IFN-alpha challenge on Day 11)
150 mg qd - Day 13 (+ IFN-alpha challenge on Day 11)
Log-Linear scale

Figure 5



Actual values +/- SD
0
10
20
30
40
predose
1h
3h
6h
9h
12h
24h
48h
120h
Time point (hours)
Treatment group:
Pooled Placebo with IFN-alpha challenge
30 mg qd with IFN-alpha challenge
90 mg qd with IFN-alpha challenge
150 mg qd with IFN-alpha challenge

Figure 6



treatment
Placebo_0
Comp.1-30 mg
Comp.1-90 mg
Comp.1-150 mg
Time_post_dose
0
1
3
6
9
12
24
48
120
treatment
Time_post_dose
STAT3
TACSTD2
SOCS1
AL445490.1
IFIT2
IFIT1
TENT5A
IFIT5
EIF2AK2
STAT1
MX1
CMPK2
HERC5
LINC01410
LAMP3
EPSTI1
IFI44
OAS3
OAS2
RSAD2
USP18
IFIT3
OASL
B2M
LY6E
OAS1
IFI6
SIGLEC1
IFI44L
IL6R
IL6ST
IFNAR1
IFNAR2
CXCL10

Figure 7



Percentage of subjects achieving % CfB or less
100%
80%
60%
40%
20%
0%
-75%
PASI 75
-50%
PASI 50
-25%
0%
25%
PASI Percent change from baseline
Treatment group
Comp. 1
50 mg
Comp. 1
150 mg
Placebo

Figure 8




% of subjects with PASI 50 response
0
5
10
15
20
25
30
35
40
Week 1
Week 2
Week 4
Follow-up 1
Follow-up 2
Treatment group
Comp. 1
50 mg
Comp. 1
150 mg
Placebo

Figure 9


% of subjects with PASI 75 response
0
5
10
15
20
Week 1
Week 2
Week 4
Follow-up 1
Follow-up 2
Treatment group
Comp. 1 50 mg
Comp. 1 150 mg
Placebo